Dirk-Jan Opstelten, PhD, Chief Scientific Officer, EPIWatch, is an independent life science consultant whose goal is to support the development and medical application of EPIWatch. With >20 years of experience in the pharmaceutical/biotech industry, he has developed leadership skills to manage complex R&D projects. His professional background, experience and achievements include: R&D management at HAL Allergy (Leiden, the Netherlands) as Chief Scientific Officer, and project management at J&J subsidiary Crucell (Leiden, the Netherlands) as Project Director, Biologicals. Under his leadership two new pharmaceutical allergy products were granted regulatory approval in 2018, and a new immunotherapeutic drug for peanut allergy was brought from research into clinical development under a US FDA-approved IND application. Dr Opstelten holds a PhD from Utrecht University (the Netherlands).